Literature DB >> 10448299

Familial risks in second primary breast cancer based on a family cancer database.

K Hemminki1, P Vaittinen.   

Abstract

The nationwide Swedish Family Cancer Database was used to analyse the risk of breast cancer in daughters of mothers presenting second, bilateral breast cancer. The database contained information on family relationships and cancers of mothers and daughters when the daughter was born after 1940, totalling 55,411 maternal and 9966 daughters' primary breast cancers. Some 95% of the second breast cancers were diagnosed in the contralateral breast. Familial risk of breast cancer in daughters was 1.70 when the mothers had first breast cancer and 3.28 when the mothers had bilateral breast cancer. Thus, the increased familial effect of the second breast cancer was 1.93. The risk was highest in daughters diagnosed at a young age when the mother was diagnosed before 50 years of age. If the mothers had breast cancer following any other type of cancer, the familial effect was as for the first breast cancer (1.03). The age of onset for breast cancer in daughters was 0.7 years younger for those whose mother had bilateral as compared with unilateral breast cancer, although the difference was not statistically significant. The mothers with bilateral breast cancer whose daughters also had breast cancer were diagnosed with the first breast cancer 3.8 years younger than mothers whose daughters did not have breast cancer. The present results apply to a relatively young population of daughters (< 54 years of age).

Entities:  

Mesh:

Year:  1999        PMID: 10448299     DOI: 10.1016/s0959-8049(98)00378-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.

Authors:  Anne S Reiner; Julia Sisti; Esther M John; Charles F Lynch; Jennifer D Brooks; Lene Mellemkjær; John D Boice; Julia A Knight; Patrick Concannon; Marinela Capanu; Marc Tischkowitz; Mark Robson; Xiaolin Liang; Meghan Woods; David V Conti; David Duggan; Roy Shore; Daniel O Stram; Duncan C Thomas; Kathleen E Malone; Leslie Bernstein; Jonine L Bernstein
Journal:  J Clin Oncol       Date:  2018-04-05       Impact factor: 44.544

2.  The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients.

Authors:  Xinrui Liang; Danhua Li; Wenwen Geng; Xuchen Cao; Chunhua Xiao
Journal:  Tumour Biol       Date:  2013-01-09

3.  Second primary breast cancer occurrence according to hormone receptor status.

Authors:  Allison W Kurian; Laura A McClure; Esther M John; Pamela L Horn-Ross; James M Ford; Christina A Clarke
Journal:  J Natl Cancer Inst       Date:  2009-07-09       Impact factor: 13.506

4.  Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.

Authors:  J O Culver; C D Brinkerhoff; J Clague; K Yang; K E Singh; S R Sand; J N Weitzel
Journal:  Clin Genet       Date:  2013-02-20       Impact factor: 4.438

5.  Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.

Authors:  Anne S Reiner; Esther M John; Jennifer D Brooks; Charles F Lynch; Leslie Bernstein; Lene Mellemkjær; Kathleen E Malone; Julia A Knight; Marinela Capanu; Sharon N Teraoka; Patrick Concannon; Xiaolin Liang; Jane C Figueiredo; Susan A Smith; Marilyn Stovall; Malcolm C Pike; Robert W Haile; Duncan C Thomas; Colin B Begg; Jonine L Bernstein
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

6.  Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.

Authors:  Jennifer D Brooks; Esther M John; Lene Mellemkjaer; Charles F Lynch; Julia A Knight; Kathleen E Malone; Anne S Reiner; Leslie Bernstein; Xiaolin Liang; Roy E Shore; Marilyn Stovall; Jonine L Bernstein
Journal:  Cancer Med       Date:  2016-10-03       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.